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Hella A. Bolck* , Chantal Pauli, Elisabeth Göbel, Katharina Mühlbauer,
Susanne Dettwiler, Holger Moch and Peter Schraml
Department of Pathology and Molecular Pathology, University Hospital of Zürich, Zurich, Switzerland
Biorespositories of formalin-fixed and paraffin-embedded (FFPE) or fresh frozen human
tissues from malignant diseases generated as integral part of the diagnostic workup
in many pathology departments have been pivotal resources for translational cancer
studies. However, such tissue biobanks have traditionally contained only non-viable
specimens and thus cannot enable functional assays for the discovery and validation of
therapeutic targets or the assessment of drug responses and resistance to treatment.
To overcome these limitations, we have developed a next-generation comprehensive
biobanking platform that includes the generation of patient-derived in vitro cell models
from colorectal, pancreatic and kidney cancers among others. As such patient-
derived cell (PDC) models retain important features of the original human tumors,
they have emerged as relevant tools for more dynamic clinical and experimental
analyses of cancer. Here, we describe details of the complex processes of acquisition
and processing of patient-derived samples, propagation, annotation, characterization
and distribution of resulting cell models and emphasize the requirements of quality
assurance, organizational considerations and investment into resources. Taken together,
we show how clinical tissue collections can be taken to the next level thus promising
major new opportunities for understanding and treating cancer in the context of
precision medicine.
Keywords: tissue biobanking, living cell biobanking, patient-derived tumor models, organoids, personalized
medicine
INTRODUCTION
Despite significant progress made in understanding and treating cancer in the last decades, this
disease is still one of the leading causes of mortality worldwide (Siegel et al., 2016). Progress in
cancer management has recently resulted from the advent of new sequencing technologies that have
made it increasingly feasible to identify cancer-specific genomic alterations. Even though, this has
provided rationales for the development of novel targeted therapies, the average number of new
drugs approved for cancer therapy has surprisingly declined at the same time (Hay et al., 2014).
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A major reason for this apparent failure to translate promising
drug candidates from the bench to the bedside can certainly
be attributed to the inadequate use of model systems for
human cancer research. To date, pre-clinical studies and
screening programs of potential anti-cancer drugs have
mostly utilized immortalized cell lines which often fail to
recapitulate fundamental biological features of human tumors
(Beroukhim et al., 2009; Horvath et al., 2016). Realizing these
inherent limitations, there has been a growing need for more
pathophysiological relevant cell culture tools that can be used
to study tumor biology and consequently to rationally design
precision treatment strategies.
Patient-derived cell (PDC) models generated from surgical
biopsy specimens have recently emerged as desired pre-clinical
tools. PDC models are characterized by increasing complexity
and biological relevance as they retain patient-specific features
and are amenable to a variety of experimental applications (Pauli
et al., 2017; Drost and Clevers, 2018; Vlachogiannis et al., 2018;
Bolck et al., 2019). Thus they have the potential to functionally
complement molecular and pathological tumor analysis and
advance precision oncology while at the same time fulfilling
the current need for more relevant cell culture systems for
cancer research.
In the Department of Pathology and Molecular Pathology
at the University Hospital Zürich, we have developed a
comprehensive biobanking platform that has evolved from
our extensive routine sample collection of biospecimens from
malignant human tumors and includes the generation of patient-
derived in vitro cell models. Here, we describe the main
aspects of this biobanking strategy detailing processes such
as the acquisition of PDCs, and the generation, annotation,
characterization and distribution of resulting cell models. We
discuss in detail how clinical tissue biorepositories can be
advanced to enable functional studies and personalized oncology
and relate to our experience in developing a living cell biobank
alongside the diagnostic workup.
A COMPREHENSIVE BIOBANKING
STRATEGY OFFERS NOVEL
OPPORTUNITIES FOR BASIC,
TRANSLATIONAL AND CLINICAL
RESEARCH
Hundreds of clinical samples are obtained every day in routine
pathology practice where they are processed for diagnostic
purposes. Generally, a large proportion of these samples
originates from surgical resections of tumors. These tissue
specimens are routinely archived as FFPE blocks, the gold
standard material for histological and immunohistochemistry
analysis and simultaneously assembled into biobanks that are
stored for many years (Moch et al., 1999; Schraml et al., 1999;
Bubendorf et al., 2001). These pathology collections have been
the most prevalent in the origins of biobanks as they have
formed the basis for patient diagnoses. Out of the recognition that
such collections of annotated samples can provide an excellent
resource for biomedical research, tumor tissue biobanking has
been constantly growing and gaining importance (Vaught,
2016; Coppola et al., 2019). With the advent of molecular
pathology, snap freezing of OCT-embedded pieces of adjacent
cancer and normal tissue have become critical aspects of tissue
biobanking (Steu et al., 2008) because these specimens allow
more comprehensive genomic, transcriptomic or proteomic
studies (Figure 1A). As pathological examination of fresh frozen
tissue samples is usually not part of the routine diagnostic
workflow, Hematoxylin and eosin (HE)-stained cryostat sections
need to be reviewed by a designated pathologist to ensure that
morphological parameters of the frozen sample such as tumor
cell content, stromal components, and presence of necrosis
are recognized before embarking on sophisticated molecular
profiling studies. Importantly, with these approaches, thousands
of samples have been collected by the tissue biobank at our
department. This is illustrated by the number of specimens that
were stored in the five year period (beginning of 2014 to the end
of 2018) that we focus on in this article (Figure 1B).
The retrospective analysis of these high-quality and readily
available repositories that are linked with relevant clinical and
pathological information allows the definition of cohorts for
example for the creation of tissue microarrays or libraries of
high quality nucleic acids for high-throughput molecular analysis
(Figure 1A). Thus, these are extremely valuable for the evaluation
of tumor subtypes, cellular and molecular heterogeneity and
for the discovery and validation of biomarkers. However, given
that all tissue is fixed or frozen and thus non-viable, such
traditional tissue biobanks cannot provide tools for the discovery
and validation of therapeutic targets or the assessment of drug
response, cancer progression or resistance to treatment. In order
to provide pre-clinical cancer models that are amenable to
functional assays, we have complemented our large longitudinal
collection of formalin-fixed tumor biopsies and fresh frozen
tissues with viable PDC models (Figure 1A). In the subsequent
sections, we describe main aspects of the extensions we made
to traditional tissue collection with the aim to establish a living
cell biobank of patient-derived in vitro cell models in order to
promote cancer research and precision medicine.
TECHNICAL, ORGANIZATIONAL AND
PROCEDURAL REQUIREMENTS FOR
ESTABLISHING A LIVING CELL BIOBANK
Even more than traditional biobanking, the generation and
maintenance of a living cell biobank requires a significant
regulatory, administrative and laboratory infrastructure and the
coordinated efforts of multiple teams. Setting defined criteria for
the identification of tumor specimens that should be included
into living cell biobanking was a first essential step to manage the
workflow as it was neither feasible nor practical to collect samples
from all tumor patients. In our living cell biobank, we specifically
collect specimens from tumor types that will be integrated into
running projects by our collaborating investigators. These have
predominantly included renal cell carcinoma (RCC), pancreatic
ductal adenocarcinoma (PDAC) and colorectal cancer (CRC).
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FIGURE 1 | Collection of human tumor tissue for diagnostic purposes and biobanking. (A) Diagram summarizing the workflow for surgical specimen and biopsy
processing in the Department of Pathology and Molecular Pathology (University Hospital Zürich). Fresh tissue is sectioned and consequently formalin-fixed and
paraffin-embedded (1) or fresh frozen (2). If available, the remainder of tumor tissue is processed in the living cell biobank to establish 2D and 3D cell models (3).
Fresh tumor tissue and cells from established culture models are viably frozen for biobanking purposes. In addition, the repositories of fixed and cryopreserved
tumor-derived biospecimens can be further extended, e.g., by collecting matched body fluids (e.g., blood or urine). (B) Number of cases in which tumor samples
were collected by the tissue and living cell biobanks of the Department of Pathology (University Hospital Zürich) from January 2014 to December 2018. Numbers for
patients with specific diagnoses that were included in living cell biobanking are indicated separately (renal cell carcinoma [RCC], colorectal cancer [CRC] and
pancreatic ductal adenocarcinoma [PDAC]). A summary of case numbers encompassing all malignancies which were considered for biobanking are presented as a
reference. Native tissues collected for living cell biobanking from other malignancies than RCC, PDAC and CRCs were not always taken into culture. Instead viable
cells were cryopreserved and thus the number of established cell models was not determined (N/A). (C) Diagram depicting the generation of PDC models from
native patient tissue using tumor type-specific media components. Representative images of surgical specimens obtained for living cell biobanking are shown in the
top panel.
Other tumor types have been considered but still play a minor
role for our biobanking activities and will not be further described
here. Besides being the tumor type of our interest, specimens
entering the living cell biobank should ideally have a minimum
size of about 0.5 cm3. Even though establishing cell models from
smaller specimens can be successful, this ensures that some of the
original material can be viably frozen in parallel with cell culture
derivation. In daily practice, the size of suitable tumor specimens
usually ranges between 0.5 and 8 cm3 (Figure 1C). Upon first
screening, we also consider that patients may have infectious
diseases such as Hepatitis, HIV or tuberculosis. Processing
samples from these patients can potentially pose a risk to research
personnel and should therefore not be performed. Of note, a
large proportion of specimens cannot be included in living cell
biobanking because the resected tissue is required entirely for
diagnostic purposes, which have priority over biobanking and
research. Thus, only a subset of tumors could be subjected to PDC
culture generation each year (Figures 1A,B).
If sufficient tissue was available, suitable pieces were selected
for living cell biobanking by a board-certified pathologist and
subsequently collected by the biobanking team in cold, sterile
RPMI medium. Subsequently, all specimens were subjected
to mechanical disaggregation and afterwards further processed
according to previously described methods (Figure 1C; Boj et al.,
2015; van de Wetering et al., 2015; Pauli et al., 2017; Bolck
et al., 2019). Tumor organoids were generated from CRC and
PDAC samples using a 3D cell culture system based on growth
factor-reduced Matrigel, while RCC-derived cells were subjected
to monolayer cell culturing and tumor organoid formation in
parallel (Figures 1C, 2A). This strategy was based on our previous
findings that both 2D and 3D PDC models capture important
biological features of human clear cell RCC (Bolck et al., 2019).
In this context, it is important to note that even though the
information represented by 2D and 3D cell cultures can vary,
both models offer important insights into tumor biology (Xu
et al., 2014; Stock et al., 2016; Carragher et al., 2018; D’Agosto
et al., 2019). Thus, while there has been no demand for 2D in vitro
models of CRC or PDAC, we continue to rely on monolayer cell
culture systems for models derived from human RCC tissue.
A total of 99 RCCs, 24 CRCs and 33 PDACs were subjected to
PDC cultures derivation from 2014 to 2018. In vitro cell models
could be established from 60% of the RCC, 46% of the CRC
and 42% of the PDAC tissue samples (Figure 1B). According
to our observations, lack of viable cells upon culture initiation
or no significant cell proliferation after culture derivation were
the main reasons for the initial failure to generate PDC models.
In addition to establishing cell culture models, fractions of the
dissociated cells or disaggregated clusters from primary tissues
were routinely cryopreserved as a reference and for “future-
proofing” in order to ensure that emerging technologies can be
set up using the native tumor populations (Figure 1C).
In general, the protocols for PDC model derivation,
propagation and collection of derivatives for characterization
and other experiments (e.g., cell pellets, DNA extractions, FFPE
embedded cell pellets, etc.) were subject to project-specific
considerations that we undertook in collaboration with the
principle investigators and which preceded any research project
involving PDC models from our living cell biobank. In the
last years, 3D tumor organoids have been usually maintained
under serum-free conditions with growth factors that mimic
the in vivo stem cell niche (e.g., the Wnt-agonist R-spondin
1, the transforming growth factor beta (TGF-b) inhibitor
Noggin) (Figure 1C; Boj et al., 2015; van de Wetering et al.,
2015; Baker et al., 2016). Cells derived from RCCs frequently
grew in monolayers requiring a reduced set of growth factors
(Figure 1C). These growth conditions stimulated proliferation
for only shorter periods and PDC cultures usually became
senescent after approximately 10 passage doublings. However,
as early passages resembled the original tumor closely in terms
of genetic and cellular heterogeneity, these can still provide a
simple and robust model system for studying specific aspects of
tumor biology (Bolck et al., 2019). Growth rates were strongly
variable between patient-derived samples. Once established,
PDC cultures were expanded by serial passaging for at least
three population doublings with the goal of cryopreserving
viable cells for biobanking purposes. Nevertheless, most cell
models continuously proliferated for more than 5 passages
and a significant fraction have been maintained in culture
beyond passage 20.
STRINGENT CHARACTERIZATION AND
VALIDATION ENSURES PDC MODELS
ARE REPRESENTATIVE OF THE HUMAN
TUMOR
During the propagation phase, morphologies of PDC models
were continuously assessed by bright-field microscopy and
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FIGURE 2 | Comprehensively characterized patient-derived cancer models are collected for the living cell biobank that is accessible for cancer research and
precision medicine. (A) Representative bright field microscopy of patient-derived models from renal cell carcinoma (RCC), colorectal cancer (CRC) and pancreatic
ductal adenocarcinoma (PDAC) depict gross morphology during in vitro cell growth (X10 objective, scale bar denotes 50 µm). HE-stained slides show histology of
the tumor monolayer or organoid cultures in comparison to matched tumor tissues demonstrating that histopathologic features are largely preserved (X10 objective,
scale bar denotes 100 µm). (B) Pap–stained cytological smears (X20 objective, scale bar denotes 100 µm) of tumor organoids indicate characteristic features of
malignancy. Immunohistochemistry (IHC) staining displaying concordant expression of cytokeratins (pan-Cytokeratin for RCC and CK19 for PDAC and CK20 for
CRC specimens) in the cell models and matched patient tumor tissues (X10 objective, scale bar denotes 100 µm). Cancer driver mutations characteristic for each
case were present in the original tumor and patient-derived cell models. Representative Sanger sequencing profiles are shown for each case. (C) Bar chart of
surgical specimens that were considered for the generation of PDC models over 5 years. Cell model derivation was not possible if no viable cells remained following
tissue processing or cells did not proliferate sufficiently for at least three population doublings (gray – no culture possible). For further validation, primary tumor
samples and corresponding PDC models were subjected to targeted sequencing analysis of cancer driver genes. This included the assessment of VHL mutations
for clear cell RCCs, MET amplifications in papillary RCCs and KRAS mutations in PDACs and CRCs. The number of PDC cultures retaining the alterations of the
original human tumors is indicated (green - successful). Tumors and corresponding cell cultures without known cancer mutations were not comprehensively analyzed
(orange - open). PDC models that did not retain the mutation of the human tumor are marked as “failed” (red). (D) Diagram depicting the general structure of the
databases used for biobanking. Diagnostic and patient related data is available through the clinical data center and the pathology reporting database. These contain
sensitive patient data and are therefore not accessible for external researchers. The designated biobanking IT infrastructure collects all patient and sample related
information in a pseudonymised way. Researchers who have obtained ethical and review board approval can obtain FFPE and fresh frozen tissue as well as PDC
models through this biobanking infrastructure.
typical phenotypes like the glandular structures displayed by
many CRC-derived organoids were recorded (Figure 2A). In
addition, stringent validation and characterization was required
before initiating additional analyses to ensure that the PDC
models retained specific features of the original human tumors
and were not contaminated with non-tumor or stromal cells. An
initial histopathological analysis of HE-stained tissue and tumor
model sections benefited from the key expertise in pathology in
our department. It could often already provide first confirmation
of the presence of typical cancerous features such as cells
with enlarged and polymorphic nuclei or conspicuous nucleoli
(Figure 2B). Cytological smears prepared from tumor organoids
presented another quick method to screen whether these PDC
models contained cells with malignant features (Figure 2B;
Pauli et al., 2016). To further verify that PDC models showed
concordance with the original tumor tissue, protein expression
patterns were assessed by immunohistochemistry (IHC). To
illustrate this method, expression of cytokeratins (CK19, CK20
or pan-cytokeratin) is shown in Figure 2B which confirms the
epithelial origin of patient tumors and matched PDC models.
Even though we found IHC analysis to be a suitable tool to
verify the origin of cell type, according to our observations it
was often insufficient to unequivocally distinguish cancer cells
from normal epithelial cells. The analysis of genetic cancer
driver events was a more reliable method to exclude that
PDC cultures contained predominantly benign epithelial cells.
Extensive genomic profiling by whole-genome or whole-exome
DNA sequencing of the original tumor and corresponding
PDC models, preferably over several passages and after freeze-
thaw would be the gold standard to confirm that cell models
represent the mutant cancer cells. With such approaches, it is
not only possible to unambiguously verify whether the genomic
profiles of tumors and corresponding in vitro cell models
match but additionally, details about subclonal composition
and their dynamics can be deducted from the large-scale
sequencing datasets. This potentially allows grouping cases
according to mutational signatures or even unveils information
about treatment targets (Sachs et al., 2018; Tiriac et al., 2018).
However, extensive molecular sequencing is costly and requires
advanced bioinformatics analysis. In our living cell biobanking
workflow, we therefore routinely employ less sophisticated
methods such as targeted sequencing for PDC model validation
(Figure 2B). In cases for which characteristic molecular features,
such as point mutations in tumor-associated genes were known
from the clinical workup, this straight-forward approach was
sufficiently informative and could confirm that PDC models
retained the cancer driver events. Here, this is exemplified by the
strategy we have employed for cell models derived from clear
cell renal cell carcinoma (ccRCC). Importantly, ccRCCs often
harbor mutations in the VHL tumor suppressor gene (80–90%
of ccRCCs) that can be easily analyzed by targeted sequencing
(Rechsteiner et al., 2011). In the 5-year period, in which we
derived in vitro models from ccRCCs, we could confirm the
presence of the VHL mutation of the parental tumor in 75%
(28/37) of the corresponding PDC cultures by Sanger sequencing.
Similarly, we assessed activating mutations in KRAS that are
common in CRC (30–40% of cases) and almost ubiquitous in
PDAC (Kandoth et al., 2013; Ying et al., 2016). From the CRCs
and PDACs for which we could detect a mutation in the KRAS
gene, we were able to confirm its presence in 80% of the CRC-
derived (4/5) and 90% of the PDAC-derived (10/11) tumor
organoids (Figure 2C). Only a small percentage of PDC models
failed to retain the genetic alterations of the original tumors
(23% of ccRCC-derived, 20% of the CRC-derived and 10% of the
PDAC-derived cell models). In these cases, we often observed
overgrowth of benign cells in the cultures thus corroborating
previous reports showing that also tissue-derived normal cells
can grow efficiently in vitro (van de Wetering et al., 2015; Lobo
et al., 2016; Drost and Clevers, 2018; Grassi et al., 2019; Saeed
et al., 2019). Some PDC models remained, for which single
tumor-specific molecular alterations were elusive (6 CRCs, 3
PDACs and 18 RCCs). For these cases, comprehensive molecular
profiling remained the only possibility for cell model validation
but as this exceeded our possibilities, these samples have not been
validated systematically to date. Nevertheless, in our living cell
biobank we have successfully established a considerable number
of PDC models from several tumor types that closely recapitulate
important properties of the original tumors and are therefore
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valuable tools for translational cancer research and pre-clinical
drug profiling (Figure 2C).
SAMPLE MANAGEMENT IS GUIDED BY
POLICIES AND STANDARD OPERATION
PROCEDURES
In order to ensure the availability of these well characterized,
annotated and carefully preserved biospecimens for molecular
and functional investigations, quality assurance is a key element
and requires strict adherence to standard operating procedures
(SOPs). Starting at the tissue collection procedure, control of
pre-analytic parameters (e.g., relating to the patients, sampling,
transport, processing and storage processes) is important because
these variables can potentially impact on the outcome of
analytical results. Careful annotation of these parameters may
be integrated by the Sample PREanalytical Code (SPREC),
a comprehensive tool to document pre-analytical details of
biospecimens (Lehmann et al., 2012). Another possibility is the
retrospective quality stratification that is based on examination
and validation of selected samples based on analytical parameters
(e.g., RNA integrity) (Betsou et al., 2009). These methods are
supported by the reference standard for biobanks ISO 20387
that defines minimum standardization requirements for the
organization and processing of biological samples (Coppola et al.,
2019). Both SPREC and ISO 20387 are recognized internationally
for procedure harmonization for FFPE and fresh frozen tissue
samples (Coppola et al., 2019). Importantly, in our biobanking
workflow, annotation of several key pre-analytical elements
has been implemented. From our clinical information system
it is possible to track a number of parameters (e.g., patient
data, tissue ischemia times, sampling procedures and sample
sizes) while our biobank-specific SOPs clearly define variables
concerning tissue processing (e.g., use of specialized reagents,
centrifugation speeds and storage conditions) but some other
parameters are more difficult to assess (e.g., patient fasting status,
transport conditions). However, regulation and recording of pre-
analytic variables, even though desirable, has to comply with
the circumstances of the clinical workup. Since the impact of
many of these parameters is largely unknown to date (Galissier
et al., 2016) and native tissue samples for living cell biobanking
are less readily available, we most often put emphasize on the
possibility of collecting specimens of our interest over the extent
of pre-analytical control.
Furthermore, the procurement of patient biospecimens is
subject to stringent legal and ethical regulations. Despite the
legislative frameworks that apply to biobanking activities varying
considerably among the European countries (Kaye et al., 2016),
a number of ethical considerations have to be universally
addressed. In all legislative systems, the dignity, privacy and
health of human beings that donate their tissue have to be
protected while at the same time creating a favorable framework
for research with human samples (Boers et al., 2016). In
Switzerland, the Swiss Human Research Act (HRA) regulates
both clinical and non-clinical trials involving human beings
and is thus applicable for the collection and utilization of
patient tissues and their derivatives for research purposes. For
multicenter biobanking projects across Europe, the provisions
for the use of tissue samples and data for biomedical research
can be found in different sources of law in each jurisdiction
(Kaye et al., 2016). In addition, the recently established
European General Data Protection Regulation (GDPR) that
controls data and privacy protection affects biobanks and
their guideline for specimens and personal data usage on
the European level. Internationally, collaborative platforms for
biobanks (e.g., BBMRI-ERIC-EU, ISBER) will likely play an
instrumental role to provide an adequate legal framework for
sharing samples and data potentially across many borders. In
accordance with the current guidelines in Switzerland, patients
at the University Hospital Zürich are asked to consent to
the further use of their personal data and tissue samples for
biomedical research. From the side of the investigators, ethical
approval has to be obtained from the local committee for
research projects involving data or samples associated with our
biospecimen collection. Moreover, to protect patient privacy,
all samples are pseudonymised before researchers can obtain
them for analyses (Figure 2D). To ensure correct adherence
to these guidelines, specialized personnel like study nurses and
biobanking staff are employed and an internal review board
that also includes clinicians and scientists assesses all new
projects (Figure 2D).
Besides the organizational aspects connected to the ethical
implications, documentation of all procedures concerning
origin, management and storage of samples is a key factor
for successfully biobanking and distribution of well-annotated
specimens. At the time when we started to develop our next-
generation biobanking strategy, a suitable documentation tool
for many aspects of living cell biobanking was not readily
available and therefore we developed a dedicated, comprehensive
biobanking IT infrastructure (Figure 2D). This infrastructure
was designed to interface with the clinical IT management
systems and thus allows sample annotation with relevant
demographic, pre-analytical and diagnostic information. For
the documentation of PDC models, we additionally record
growth conditions (2D/3D culture systems, specific media usage),
cell morphologies (descriptions and photos) and times of
passaging, cryopreservation and defrosting of stored samples.
In addition, the storage locations of viably frozen cells and
their derivatives (DNA, RNA, protein extracts, etc.) can be
tracked and since all records have been de-identified the
dedicated biobanking databases for fresh frozen tissue and
PDC models can be opened up for external researchers aiming
to select a study cohort from the available samples. Notably,
in this database also sample distribution is documented thus
enabling us to follow-up on data that was generated by external
investigators (Figure 2D).
Finally, it is fundamental to our tissue and living cell biobank
that specimens and data that we collect and store are effectively
utilized to support basic and translational biomedical research.
In order to demonstrate such value, our ongoing endeavors are
directed toward sustaining and expanding our living cell biobank
workflow alongside the traditional tumor tissue biorepository for
future cancer research and clinical application.
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DISCUSSION
Advances in molecular medicine have significantly increased our
understanding of cancer biology in the last two decades and are
spawning a paradigm shift in patient care toward personalized
treatment strategies. To realize the promise of precision therapy
in the clinics, a strong link between pathological data, molecular
alterations, phenotypical consequences and patient outcomes
will be instrumental. The comprehensive, tripartite biobanking
strategy of collecting FFPE, fresh frozen and patient-derived
living cells we have described here offers a toolkit for addressing
numerous questions in current and future basic, translational and
clinical research. Thus, the extension of traditional patient tumor
tissue biobanking with viably frozen PDCs and personalized
in vitro models amenable for functional assays will likely be a
major enabling factor for the discovery and development of new
diagnostic tools and precision treatment options.
However, next-generation biobanking adds a new layer of
complexity to traditional biospecimen collection as it requires
an even higher degree of coordination, resources and expertise.
For successful living cell biobanking, culture conditions for PDCs
from different tumor types have to be established separately by
expert scientific staff and each culture needs to be validated
and characterized carefully. It is important to note that growth
conditions are major influencing factors during propagation
of PDC models as they impact on cellular processes such as
replication and cell survival as well as on the genotypic and
phenotypic heterogeneity of cell subpopulations. Thus far, only
few studies have addressed the representation of tumor subclonal
cell populations and their dynamics during PDC culture (Clevers,
2016; Fujii et al., 2016; Li et al., 2018; Bolck et al., 2019). To
what extent tumor heterogeneity is changing during prolonged
cell culture and how this is influenced by growth conditions will
need to be investigated in more detail in order to understand
the translational value of these models and to determine best
practices. In the meantime, it will be paramount to cryopreserve
the original, most heterogeneous populations of tumor and
associated cells to ensure that their potential for personalized
medicine can be maximized once new technologies emerge.
As PDC models are more comprehensively studied, it is likely
that more elaborate systems will be generated, for example by
co-culturing tissue-specific stroma or immune components or
applying microfluidics and organ-on-a-chip technologies (Xu
et al., 2014; Horvath et al., 2016). Large collections of viably
frozen PDCs like the one described here will provide the
necessary tools to enable the development of such assay systems
and to explore new frontiers for their use. In this process, it is
essential that joint oversight of pathologists and scientists will
ensure that the selected biospecimens are representative and
adequate for the intended study and all organizational, ethical
and legal requirements are met.
CONCLUSION
Based on our five years of experiences in next-generation
biobanking we illustrate a targeted but scalable workflow that
can be adjusted to accommodate a variety of research needs or
adapted in other pathology departments. We strongly believe
that in conjunction with traditional tissue biobanking, a living
cell biobank will constitute an important tool for functional
cancer research and personalized medicine which at the same
time has the potential to fulfill the current demand for
more reliable, patient-specific cancer models. However, it is
important to note that for next-generation biobanking, additional
considerations and long-term investments (e.g., specialized staff,
IT resources, equipment and infrastructure) are required in
order to preserve the integrity of these collections for future
research. This may necessitate transformational changes in
research and infrastructure environments that often go beyond
current standards for tissue specimen collection in pathology
departments. Nevertheless, next-generation biobanking promises
major new opportunities for cancer patients and will most likely
play a decisive role in advancing precision medicine.
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